美托洛尔联合曲美他嗪治疗冠心病心力衰竭临床疗效分析  

Clinical Efficacy of Metoprolol Combined with Trimetazidine in Treatment of Coronary Heart Disease and Heart Failure

作　　者：韩晓阳 王莎 HAN Xiao-yang;WANG Sha(Department of Cardiovascular Medicine,Yuxian People’s Hospital,Yuxian,Hebei 075700,China;Department of Nephrology,Yuxian People’s Hospital,Yuxian,Hebei 075700,China)

机构地区：[1]蔚县人民医院心血管内科,河北蔚县075700 [2]蔚县人民医院肾内科,河北蔚县075700

出　　处：《河北北方学院学报（自然科学版）》2024年第12期29-32,共4页Journal of Hebei North University:Natural Science Edition

摘　　要：目的探讨美托洛尔联合曲美他嗪对冠心病所致心力衰竭患者的临床治疗效果。方法120例冠心病心导致力衰竭患者按数字表法随机分为对照组和观察组各60例。对照组单用曲美他嗪治疗,观察组在曲美他嗪治疗的基础上加用美托洛尔。比较2组患者治疗总有效率及治疗前后心功能指标、心率、血浆BNP、血管内皮功能、炎性因子水平的变化。结果观察组治疗总有效率为98.33%,显著高于对照组的85.00%(P<0.05)。治疗后,2组患者LVEF显著上升,LVEDD、LVESD显著降低,观察组变化均显著优于对照组(P<0.05)。治疗后2组患者心率、血浆BNP水平均显著降低,观察组低于对照组(P<0.05)。治疗后,2组患者NO、CGRP显著上升,ET显著下降,观察组变化更为显著(P<0.05)。治疗后2组患者血清炎性因子(CRP、TNF-α)水平均降低,观察组低于对照组(P<0.05)。2组不良反应发生率(气喘、呼吸困难)差异无统计学意义(P>0.05)。结论美托洛尔联合曲美他嗪治疗冠心病所致心力衰竭患者可显著提高总有效率,改善患者心功能,调整心率和血浆BNP水平,改善血管内皮功能,降低血清炎性因子水平,不明显增加不良反应事件,具有积极临床应用价值。Objective To investigate the clinical effect of metoprolol combined with trimetazidine on patients with coronary heart disease and heart failure.Methods A total of 120 patients with coronary heart disease and heart failure were randomly divided into control group and observation group according to the digital table method,with 60 cases in each group.The control group was treated with trimetazidine alone,and the observation group with metoprolol on the basis of trimetazidine treatment.The total effective rate of treatment and the changes of cardiac function indexes,heart rate,plasma BNP,vascular endothelial function and inflammatory factors before and after treatment were compared between the two groups.Results The total effective rate of the observation group was 98.33%,which was significantly higher than 85.00%of the control group(P<0.05).After treatment,LVEF in the observation group increased significantly,LVEDD and LVESD decreased significantly,and the changes were significantly better than those in the control group(P<0.05).LVEF in the observation group decreased significantly,and those in the observation group were more significant(P<0.05).NO and CGRP increased significantly,ET decreased significantly,and the changes in the observation group were more significant(P<0.05).The indexes of the observation group were significantly decreased(P<0.05).There was no statistically significant difference in adverse events(asthma,dyspnea)between the two groups(P>0.05).Conclusion Metoprolol combined with trimetazidine in the treatment of patients with coronary heart disease and heart failure can significantly improve the total effective rate,improve the cardiac function of patients,adjust the heart rate and plasma BNP level,improve vascular endothelial function,reduce the level of serum inflammatory factors,and do not significantly increase adverse events,which has positive clinical value.

关 键 词：冠心病 心力衰竭 曲美他嗪 美托洛尔 

分 类 号：R541[医药卫生—心血管疾病]